Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Last Thursday, Pfizer announced a $75 million settlement with Nigeria’s Kano state government to resolve claims that the pharmaceutical company was responsible for the death or disabling of dozens of children in a 1996 clinical study of the Pfizer antibiotic Trovan. Pfizer will establish a $35 million fund for people who participated in the trial, underwrite $30 million in health care initiatives in Kano, and pay $10 million to cover the state’s legal costs. In return, the state — which initially sought more than $5 billion — agreed to drop all civil and criminal charges against Pfizer, which has always maintained that the deaths and injuries were the result of meningitis, not its drug. But Pfizer hasn’t bought peace in all of the litigation stemming from the Trovan study. Nigeria’s central government has pending civil and criminal cases against the company, and a lawyer for Kano told The Washington Post that the Kano settlement does not resolve the federal cases, in which Nigeria seeks almost $7 billion. Moreover, as the Litigation Daily has previously reported, the 2nd U.S. Circuit Court of Appeals in January revived an Alien Tort Claims Act class action brought on behalf of the children allegedly harmed in the Trovan trial. Richard Altschuler of Altschuler & Altschuler, who represents more than 50 plaintiffs in the class action, told The Associated Press that news of the Kano settlement made him optimistic. “I think it’s encouraging, and it may be a very significant step [toward resolution],” he said. (He declined further comment to the Litigation Daily.) Pfizer, which is represented by Kaye Scholer in the U.S. Trovan litigation, said in an e-mail statement that it is trying to settle that case as well. “We believe settlement is in the best interest of all parties to the remaining Trovan litigation,” the statement said. “We are pursuing discussions toward that goal.”

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.